New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
06:10 EDTSGYPSynergy Pharmaceuticals' plecanatide shows positive results in Phase 2B study
Synergy Pharmaceuticals announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation. The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement frequency – the study’s primary endpoint – and was safe and well tolerated. The most common event was diarrhea, which occurred in 9.3% of the 3.0mg plecanatide-treated patients. The company intends to initiate pivotal phase 3 trials in IBS-C patients in 2H14.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:45 EDTSGYPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
10:18 EDTSGYPHigh option volume stocks
High option volume stocks: BTX ALL FIVE SGYP SWFT RHT IDCC NVS WGO XBI
10:06 EDTSGYPSynergy Pharmaceuticals talking to advisers about possible sale, Bloomberg says
March 16, 2015
18:21 EDTSGYPSynergy Pharmaceuticals reports Q4 EPS (32c), consensus (28c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use